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Magnetic Resonance Imaging-guided Breast Biopsies: Tips and Tricks
Elissa R. Price, MD*, Elizabeth A. Morris, MD
Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, NYAs a robust imaging modality, magnetic resonance
imaging (MRI) of the breast offers sensitivity that
approaches 100% for invasive carcinoma and approaches
80%e90% for in situ carcinoma [1e4]. As with all breast
imaging modalities, there is an overlap between benign and
malignant features which necessitate biopsy [5,6]. Because
many lesions identified on MRI will be occult on other
imaging modalities, biopsy under MR (magnetic resonance)
guidance is an integral part of any breast imaging program in
today’s imaging paradigm (Figure 1). The instrumentation
and basic methodology for MRI-guided biopsies performed
at Memorial Sloan-Kettering Cancer Center (MSKCC) was
previously reviewed [7]. With this methodology as a foun-
dation, and based on the institution’s experience with over
2000 biopsies, we present 10 tips that we have found useful
in performing this procedure safely, accurately, and
efficiently.Background
WeperformMRI-guided biopsies by using a 1.5- or 3-Tesla
magnet. As per the 2008 American College of Radiology
(ACR) Practice Guideline [8], images should be acquired at
a slice thickness of 3 mm or less, with the goal of approxi-
mately 1-mm in-plane resolution. A basic biopsy protocol
should include fat-suppressed images (fat suppression is
preferred over subtraction and is easily achievable on most
current MRI systems); a bright fluid sequence (T2 or short-tau
inversion recovery); pregadolinium T1-weighted, and several
dynamic postgadolinium T1-weighted images [8].
We perform neither MRI-guided fine needle aspirations
nor automated true-cut core needle biopsies, as both often
yield an insufficient sample for diagnosis and may require
extreme precision in targeting. In addition, these devices
require removal of the needle from the breast after obtaining* Address for correspondence: Elissa R. Price, MD, Department of
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insertion with directional sampling of small targets (smaller
than 10 mm) and rapid collection of a significantly larger
volume of tissue [9], both highly advantageous in the MR
environment. While an average 14-gauge core needle biopsy
device collects 17 mg of tissue, a 9-gauge vacuum-assisted
device (that commonly used for MRI-guided biopsies)
collects 200 mg [10].
Although handheld, multi-insertion MRI-compatible
vacuum biopsy systems exist, we use a console system (ATEC;
Hologic, Bedford, MA) in which the biopsy device is con-
nected by tubing to a separate console, which remains outside
the MRI suite. Console systems allow the biopsy device to be
inserted a single time for continuous, rapid, vacuum-assisted
sampling [11]. Local anesthetic can be continuously intro-
duced through a side port, which leads to less patient
discomfort [11]. The console system also provides stronger
suction, which allows targeted tissue sampling, even when the
accuracy of probe insertion is suboptimal or when, because of
technical or patient-related limitations, the probe cannot be
inserted precisely into the target. Stronger suction also facili-
tates improved hematoma evacuation [11].Tip 1: ‘‘Position, Position, Position’’
We perform breast biopsies under MR guidance with the
patient prone in a dedicated breast coil. Proper positioning of
the breast is key to a procedure that is both technically
successful and is well tolerated by the patient (Figure 2). As
much breast tissue as possible should be pulled into the coil
and placed behind the grid, with particular attention paid to
medial tissue and axillary tail tissue. This process allows
adequate compression and thickness to accommodate the
probe. Therefore, MRI technologists specifically trained in
breast positioning are essential. If no trained MRI technol-
ogist is available, a mammographic technologist assists us in
the MRI suite. The experience of these mammographic
technologists in positioning the breast for stereotactic biopsy,
in which the patient is also prone, makes them highly skilled
at this task. They are particularly invaluable in positioningll rights reserved.
Figure 1. Segmental non-masslike enhancement in the lower breast seen on screening MRI in high-risk patient. (A) No abnormality was seen on mammography
or ultrasound. Skin entry site of MRI-guided biopsy. (B) Obturator in good position within non-masslike enhancement. (C) Extensive non-calcified ductal
carcinoma in situ was found on pathology.
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posterior breast, upper inner quadrant, and subareolar
regions. Before initiating patient positioning, the radiologist
should review the diagnostic images with the technologist
and illustrate where the grid should be placed. It is helpful
for the radiologist to be in the MRI suite during patient
positioning and grid placement, closely supervising if not
actively participating in the process [12].
Although standard prone positioning is by far the most
common, we and others have found that placing the patient
in the prone oblique position facilitates access to the axillary
tail and posterior breast tissue [13]. Lesions located poster-
omedially can be accessed by placing the affected breast in
the contralateral coil (eg, for a posteromedial left breast
lesion, place the left breast in the right breast coil, such that
the medial left breast surface is easily accessible) (Figure 3).
Minimizing padding on the coil is also useful to reduce
elevation of posterior breast tissue [14].Figure 2. It is essential that the breast be properly positioned within the coil
to facilitate easy, safe access for biopsy.Tip 2: ‘‘Measure Twice, Cut Once’’ (Preparation)
This carpenter’s axiom succinctly emphasizes the
importance of meticulous preparation. Based on pre-
procedure images, the shortest approach to the lesion is
determined. If the lesion is central or if it is difficult to
predict the shortest approach before patient positioning, we
have a low threshold to grid the patient from both medial
and lateral. This strategy prevents the need to change grid
location after the initial noncontrast sequence. Once in place,
the position of the lesion must be related to the overlying
grid system. Vitamin E capsules are used as fiducial markers
and are taped over the expected site of the lesion. If both
medial and lateral grid plates are used, fiducials are placed
on both. A grease pen is used to draw the position of the
capsule onto a laminated sheet with a depiction of the grid
(Figure 4A) This laminated replica of the grid is then taken
from the MRI suite to the console, and this allows the site of
skin access to be determined relative to the vitamin E
capsule and lesion depth to be accurately calculated. The
planned site of skin access is then also drawn onto the
laminated sheet, which is taken back to the MRI suite to
ensure that the proper location on the patient is cleansed and
anesthetized (Figure 4B).
Speed and efficiency are of paramount importance during the
biopsy procedure. Because of the transient nature of contrast
enhancement on MRI, there is a limited window of time in
which to perform the procedure and verify needle placement.
Although contrast transit time will vary, a 15e20-minute
time frame to accomplish the task is our general rule. The more
prolonged the procedure, the more likely the contrast will wash
out and the more likely the patient is to move, resulting in
motion artifact and potentially leading to incorrect lesion
targeting. To facilitate seamless progression, 2 technologists
assist us: one inside the MRI suite, and the other operating the
biopsy console just outside the suite and running the MRI
sequence.
Figure 3. The left breast has been positioned in the right breast coil to
facilitate access to a far posteromedial lesion. Vitamin E capsule was placed
on the medial breast surface.
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in the procedure flow smoothly [12]. The technologist in the
MR suite needs to be acutely familiar with the procedure and
the instruments. A dedicated breast biopsy tray that can be
wheeled into the MR suite is prepared ahead of time. On this
tray, all the necessary tools are arranged in an organized fashion
so that once the procedure has been initiated, the radiologist has
quick and easy access to all equipment. The technologist
outside the MRI suite has an equally important role. We
routinely obtain a pregadolinium image, and this technologist
must ensure that fat saturation is adequate and uniform before
injection.During lesion sampling, this technologist controls the
biopsy console, changing between the biopsy, lavage, and
aspiration modes as the radiologist requests.
Tip 3: Ensure Adequate Breast Thickness
The number of sagittal slices multiplied by the slice
thickness determines total breast thickness. Lesion depth
from the skin surface is calculated by counting the number of
slices between the skin surface and the lesion on sagittal
images, and by multiplying by the slice thickness (the skin
surface is considered that slice on which the indentations of
the grid in the skin are best seen). With these numbers in
mind, the appropriate needle should be selected. We use an
MRI-compatible, coaxial, 9-gauge, vacuum-assisted biopsy
system (ATEC Breast Biopsy and Excision System; Hologic)
and choose between handpieces with 20-mm (standard) or
12-mm (petite) sampling apertures (Suros Surgical Systems;
Hologic). The radiologist must be cognizant that the smaller
sampling aperture collects less tissue and necessitates more
precise lesion targeting [9]. When we encounter thin breasts
that cannot accommodate even the 12-mm aperture, we
consider using the reverse compression paddle [7]. Althoughpreviously used to increase breast thickness for stereotactic
biopsies in thin breasts, this tool has also been useful for
MR-guided procedures. Again, we use the expertise of our
mammographic technologists when employing this paddle.
Tip 4: Lidocaine with Epinephrine
For patients with no contraindications, we use a liberal
volume of lidocaine with epinephrine (lidocaine HCL 1% and
epinephrine 1:100,000) for deep anesthesia; 20e40 mL is
prepared and injected in split doses, with 10e20 mL admin-
istered before insertion of the biopsy device, and 10e20 mL is
administered by the device during sampling. Epinephrine may
be helpful in minimizing parenchymal hematoma formation,
which could potentially obscure the biopsy site. Initial
subcutaneous anesthesia, however, is obtained by using lido-
caine only. Epinephrine should not be administered into the
skin. After drawing up the local anesthesia, we ensure that no
air bubbles are present within the syringe or needle hub. Even
small air bubbles can cause significant artifact on the MR
image and obscure small lesions.
Tip 5: Target on the Target
When the infamous thief Willie Sutton was asked why he
robbed banks, he replied, ‘‘Because that’s where the money
is.’’ The principle underlying this quotation can be applied to
MRI-guided breast biopsy. Obtain the first and most samples
preferentially from the site where the bulk of the lesion is
present [12]. If initial images demonstrate the localizing
obturator to be eccentrically positioned within the lesion, only
obtain samples on the side(s) of the needle where the lesion is
located. This ability to sample in a designated direction is
a major advantage to the vacuum-assisted biopsy device. Early
rounds of sampling usually produce the highest yield. The
more samples that are obtained, the more hematoma in the
region and the farther the biopsy device is from the target
lesion (because the closest tissue has already been removed).
These constraints lead to diminishing returns of later sampling.
As breast imagers, we are often tempted to label lesions
according to their position on a clock face. For MRI-guided
biopsies, it is important to remember that the clock face is
relative to the grid and not to the breast or to the patient. For
example, if the bulk of a lesion is located anterior to the obtu-
rator on planning (sagittal)MRI sequences, then themajority of
samples should be obtainedwith the sampling aperture directed
towards the floor (6-o’clock axis relative to the grid). If the
lesion is posterior to the obturator on planning sequences, then
most samples are obtained with the aperture directed towards
the patient’s chest wall (12-o’clock axis relative to the grid).
Based on the calculated lesion depth and by using the
centimetre marker on the exterior of the introducer sheath,
a plastic stopper is placed at the depth to which the biopsy
device should be inserted. On many devices, this stopper
does not lock in place, and therefore, does not prevent the
device from being pushed farther into the breast during
sampling. Therefore, while obtaining samples and rotating
Figure 4. (A) A grease pen is used to document the position of the fiducials
(as marked by the letter B) on a laminated depiction of the compression grid.
(B) The laminated sheet is then taken back into the MRI suite to guide
proper selection of the skin site to be cleaned and anaesthetized.
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pressure directed towards the breast and be continuously
cognizant of the stopper position. Check the position of the
stopper before sampling is initiated and after a round of
sampling has been completed. For example, if a lesion is 5
slices from the skin surface, and slices are 3-mm thick, then
the stopper would be placed at the 15-mm mark before
sampling. If the stopper is at the 20-mm mark after sampling,
then the radiologist has inadvertently advanced the needle 5
mm during the procedure and, therefore, may have been off
target. In this case, the breast should be re-imaged to assess
where the biopsy site changes are centred. If the changes are
predominantly deep to the lesion and the lesion does not
appear to have been adequately sampled, then the device
should be repositioned and repeat sampling performed.
Tip 6: Flush Away
Some biopsy devices have the capability to lavage the
biopsy cavity with saline solution and aspirate aftersampling. Before deploying the marker and removing
the device from the breast, the radiologist needs to compare
gadolinium-enhanced pre- and postbiopsy images to ensure
that the target has been adequately sampled. In minimizing
residual high-signal blood at the biopsy site, lavage and
aspiration facilitate this assessment (Figure 5). Furthermore,
hematoma evacuation may help minimize postbiopsy marker
displacement [12].
Tip 7: Postbiopsy Mammogram
After completion of sampling, we place an MRI-
compatible marker (Suros Surgical Systems ATEC TriMark
TD Biopsy Site Marker; Hologic) to demarcate the site of
biopsy. Signal void from the marker is indistinguishable from
signal void from air introduced during the procedure.
Therefore, ensuring that the marker has deployed and
assessing its position is extremely difficult (if not impossible)
on MRI, and postbiopsy unilateral craniocaudal and medio-
lateral mammograms are always obtained. We carefully
compare the position of the marker on the mammogram with
the expected site of the lesion based on the diagnostic MR
images. Any marker displacement (or suspicion thereof)
needs to be clearly documented, particularly if future needle
localization is planned (Figure 6).
Tip 8: When the Lesion Is Not Visualized
The suspicious enhancing mass or nonmass enhancement
that warranted biopsy may not be seen at the time of the
procedure. We explain this possibility to the patient during the
informed consent process. If this is the case, we first ensure that
contrast has been properly administered into the vasculature
(ie, that there were no technical issues such as tube leakage or
interstitial injection). If contrast was administered appropri-
ately and the lesion cannot be identified, then compression is
reduced. Excessive compression has been shown to interfere
with lesion enhancement [15]. Delayed sequences are also
occasionally obtained. In general, we have not found a second
injection of gadolinium to be valuable in demonstrating the
lesion if the first injection did not successfully do so. If neither
compression reduction nor delayed sequences elucidate the
lesion, then the procedure is canceled and the patient is
scheduled for 6-month follow-up diagnostic MRI (Figure 7).
At MSKCC, approximately 8% of MRI-guided biopsies are
cancelled for such reasons (Brennan S, Sung J, Dershaw DD,
et al, ‘‘Cancellation of MRI Biopsy Due to Breast Lesion
Disappearance: Frequency and Follow-up,’’ presented at the
95th Scientific Assembly and Annual Meeting of the RSNA,
December 1, 2009, Chicago, IL).
Tip 9: Multiple Lesions
A patient with multiple lesions intensifies the need for
detailed advanced planning, with careful assessment of the
location and accessibility of each lesion. With these issues in
mind, and depending on patient cooperation level, we will
Figure 5. High-signal blood and gadolinium in the biopsy cavity (A) are removed by postbiopsy lavage and aspiration (B), thereby facilitating assessment of
sampling adequacy.
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procedure, the most suspicious lesion should undergo inter-
vention first, in case the later sites are not visualized or the
patient is unable to tolerate further imaging and/or inter-
vention. When dealing with 2 lesions in the same breast, the
primary consideration is the location of the lesions relative to
each other. It is ideal if the lesions can be positioned beneath
the grid surface simultaneously so that access to both sites
can be obtained without the need to reposition. We try to grid
both lesions, inject gadolinium, and then clean and anes-
thetize both sites. In rapid succession, both introducer stylets
are inserted within coaxial introducer sheaths. The stylets are
then replaced with localizing obturators. As necessary,
postgadolinium sequences are then used to adjust the posi-
tion of each obturator (the introducer stylet should be rein-
serted if advancement is necessary). With the localizing
obturator in place at the second site, biopsy of the first site is
performed to completion. Once the radiologist is satisfied
with sampling at the first site, the obturator is replaced andFigure 6. Postbiopsy mammogram is essential to document marker position. In t
(C) Postbiopsy craniocaudal mammogram demonstrates the marker approximateattention is turned to the second site. Biopsy of this second
site is then completed, and postbiopsy markers are deployed
at both sites.
If multiple lesions within a single breast cannot be posi-
tioned beneath the grid at the same time, then the lesions
need to be sampled sequentially. The patient should be
positioned with the grid overlying the more suspicious lesion
first and sampling at this site completed (including marker
deployment). The patient should then be repositioned with
the grid overlying the second site. If bilateral lesions are
present, then we grid both sides, inject gadolinium, and clean
and anesthetize both sides. Biopsy is then performed on the
more suspicious side, including marker deployment, before
moving to the contralateral breast. We generally do not find
washout of a second lesion (be it in the same breast or in the
contralateral breast) to impede biopsy. If washout does occur
because of the time elapsed between the gadolinium injec-
tion and biopsy at the second site, then landmarks are usually
adequate to guide the procedure successfully. Clearly, thehis case, a lesion in the superolateral cone of tissue was biopsied (A and B).
ly 3 cm medial to the site of biopsy.
Figure 7. Small enhancing mass in the medial breast (A) was not visible on the day of biopsy (B). The biopsy was canceled and the patient scheduled for
follow-up MRI in 6 months’ time.
20 E. R. Price, E. A. Morris / Canadian Association of Radiologists Journal 62 (2011) 15e21preparation and organization emphasized earlier become
even more critical in expediting the biopsy of multiple
lesions.
Tip 10: Procedure Limitations
Although MRI-guided breast biopsy has been a tremen-
dous addition to the radiologist’s armamentarium, not all
lesions are amenable to this procedure. Lesions that are far
posterior along the chest wall or deep in axillary tail may be
inaccessible despite the best attempts at positioning. Simi-
larly, superficial lesions and lesions near the nipple may be
difficult for biopsy. These instances may necessitate MRI-
guided needle localization and surgical excision.
As discussed earlier, other factors that may preclude MRI-
guided biopsy include lesions not visualized on the day of
the procedure and breasts too thin to accommodate the
sampling aperture, even with the use of the reverse
compression paddle. In addition, depending on the degree of
suspicion from the diagnostic MRI, we may consider
canceling the biopsy if a lesion demonstrates a clear decrease
in size on the day of the procedure.
Histologic Considerations
Completion of the biopsy itself is not the final step in this
procedure. Radiologic-histologic concordance is an essential
component of percutaneous breast procedures in general, and
is particularly crucial in MRI-guided biopsies in which
postprocedural verification of lesion removal is impossible
[16]. Imaging-histologic discordance occurs when the
histologic findings do not provide adequate explanation for
the observed imaging features [17]. Lee et al [16] found 7%
of MRI-guided vacuum-assisted biopsy results to bediscordant, and of the discordant lesions that were surgically
removed, malignancy was identified in 30%. In a number of
studies that assessed biopsy discordance under stereotactic
and sonographic guidance, an average discordance rate of
3% (range, 1%e8%) was found. Among the discordant cases
in those studies, malignancy was identified in 14% (range,
0%e100%) at re-biopsy [16e21]. The 30% malignancy
found by Lee et al [16] demonstrates the importance of
radiologic-histologic correlation and implies a small but
significant number of false negative MRI-guided biopsies.
The false negative rate on MRI biopsy may in part relate to
the small size of many lesions seen on MRI that are occult on
all other imaging modalities, the fact that the actual sampling
of tissue is not performed under real-time direct visualiza-
tion, and that lesion retrieval cannot be verified [17]. Perhaps
the most important underlying issue, however, is the baseline
risk underlying the patient population that generally
undergoes breast MRI and MRI-guided biopsy. These are
often high-risk patients who inherently have a higher pretest
probability of malignancy [17].
For lesions that we believe to be histologically discordant
and Breast Imaging Reporting and Data System (BI-RADS) 5
on imaging, we recommend surgical excision. Alternatively, if
histology is concordant with imaging and a specific benign
diagnosis is provided (eg. fibroadenoma or intramammary
lymph node), then follow-up MRI is recommended to
ensure that the lesion was adequately sampled to assess for
growth. Some radiologists, however, believe a specific benign
concordant diagnosis requires no further evaluation. Of 177
concordant, histologically benign lesions assessed atMSKCC,
we found that none of the missed malignancies demonstrated
growth before 6 months and thus the advantage of early
diagnosis was not lost [22]. Therefore, we recommend follow-
up at 6months, and not earlier, for benign concordant histology
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dant benign diagnosis (eg, benign breast tissue) must undergo
repeat MRI in 6 months’ time.
Another important histologic phenomenon to consider is
that of underestimation. Atypical ductal hyperplasia (ADH)
underestimation occurs when a lesion that yields ADH at
percutaneous biopsy proves to be cancer at surgery [23].
Ductal carcinoma in situ (DCIS) underestimation occurs when
a lesion that yields DCIS at percutaneous biopsy proves to be
invasive carcinoma at surgery [23]. Previous work at MSKCC
by Lee et al [24] found that, among lesions that yield pure
DCIS at 9-gaugeMRI-guided vacuum-assisted biopsy, surgery
revealed invasive carcinoma in 17%. This underestimation rate
is higher than MSKCC’s previously reported 14% for stereo-
tactic 11-gauge vacuum-assisted biopsy [25]. Among lesions
that yieldADHatMRI-guided vacuum-assisted biopsy, cancer
was identified at surgery in 38% [26], higher than 20%
underestimation rate with 11-gauge vacuum-assisted biopsy
performed under stereotactic guidance [27]. These results are
somewhat counterintuitive because larger tissue-acquisition
devices, with which sampling error is reduced, would be
expected to yield lower underestimation rates. Higher under-
estimation of both ADH and DCIS under MRI-guided biopsy
may again reflect the high baseline risk of malignancy in this
patient population [24]. This knowledge must be kept in mind
when making further management recommendations after
MRI-guided biopsy.
Conclusion
Performing MRI-guided breast biopsy in a precise, profi-
cient manner is an important skill in the current imaging
milieu.We strongly believe that extra effort in the planning and
preparation phases will improve the efficiency of the proce-
dure as a whole. Trained, knowledgeable technologists who
are familiar with breastMRI and the nuances of positioning are
essential. Targeted sampling, aimed specifically at the bulk of
the lesion, will produce the highest yield with subsequent
lavage and aspiration, which allows biopsy adequacy to be
optimally assessed. Based upon our experience with this
procedure, we have outlined a series of tips and tricks that have
been useful in both routine and complex cases.
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